Want to join the conversation?
$ALXN 2Q15 PR: Net product sales of Soliris (eculizumab) grew to $636MM, a 24% increase compared to $512.5MM in 2Q15, despite currency headwinds. Positive CHMP opinions were received for Strensiq (asfotase alfa) for Hypophosphatasia (HPP) and Kanuma (sebelipase alfa) for Lysosomal Acid Lipase Deficiency (LAL-D) in the European Union.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!